CF Industries H1 2026 EBITDA Blasts Past Base-Case; Cyclical Risk Still Lurks

What happened

CF Industries reported first-half 2026 adjusted EBITDA of $2.2 billion, with second-quarter adjusted EBITDA of $1.2 billion, as tight global nitrogen supply-demand conditions and strong operating performance drove results well above the DeepValue report’s base-case assumption of roughly $2.0 billion annually. The run-rate suggests full-year EBITDA could approach $4.4 billion, but this pace reflects an unusually favorable nitrogen price environment that history shows is unlikely to persist. While the news validates the bull scenario, the report’s WAIT rating was based on risks of nitrogen normalization and gas-spread compression that have not disappeared. Management’s emphasis on ‘tight conditions’ should be weighed against the potential for new capacity and policy shifts to loosen markets later in 2026 or 2027. Investors should remain cautious, as the stock likely trades near or above the $95 trim level following this beat, offering limited margin of safety for a cyclical turn.

Implication

The $2.2 billion in first-half EBITDA implies annualized free cash flow of over $3.5 billion, providing a large cash cushion that could fund aggressive buybacks and Blue Point spending even if nitrogen prices soften in the second half. Should nitrogen benchmarks hold near current levels through year-end, per-share value could justify a price target above $100, but the DeepValue framework suggests such conditions are fragile and subject to rapid reversal. A sudden drop in corn prices or a surge in Chinese exports would compress margins quickly, potentially cutting EBITDA to $1.5 billion or lower, which at current valuation would lead to significant stock downside. We recommend waiting for a pullback toward the $75–80 range before adding, as the WAIT rating reflects the asymmetry between short-term earnings momentum and medium-term cyclical risk. Continued strong execution on cost controls and CCS milestones could eventually shift the thesis to a BUY if accompanied by a more favorable entry price.

Thesis delta

The H1 2026 earnings surge increases the probability of the bull case (EBITDA sustained at $2.4 billion+) and may force an update to the base-case assumptions if nitrogen pricing strength continues beyond mid-2026. However, the core WAIT rating remains appropriate because the stock likely trades above the $95 trim level, and the risks of margin compression from gas spread tightening and new supply have not materially changed.